Brain Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Brain surgery encompasses a broad range of neurosurgical procedures performed on the brain, its vasculature, meninges (coverings), and surrounding skull to treat structural, vascular, neoplastic, functional, and traumatic neurological conditions. The term most commonly refers to craniotomy — an operation in which a section of the skull (a 'bone flap') is temporarily removed to gain access to the brain — though many modern neurosurgical procedures are performed through much smaller openings (keyhole, or 'minimally invasive' approaches) or entirely through natural orifices (endoscopic endonasal surgery through the nose).

Neurosurgery is performed by consultant neurosurgeons with specialist training in brain and spinal surgery, working in multidisciplinary teams that include neurologists, neuroradiologists, neuro-oncologists, neuropsychologists, physiotherapists, and speech and language therapists. The operating suite for complex brain surgery is equipped with intraoperative neuronavigation (a 3D GPS system using pre-operative MRI and CT to guide the surgeon in real time), intraoperative MRI or CT to confirm extent of resection, cortical and subcortical mapping to identify critical eloquent brain areas (motor cortex, Broca's and Wernicke's speech areas), neuroelectrophysiological monitoring (somatosensory evoked potentials, motor evoked potentials, ECoG), and fluorescence-guided surgery (5-ALA fluorescent dye that accumulates in high-grade glioma cells, enabling the surgeon to visualise tumour margins under blue-violet light).

Brain surgery is typically a treatment of last resort or a necessary intervention when the neurological condition cannot be adequately managed with medications, radiosurgery, or other non-invasive approaches. The decision to operate requires detailed multidisciplinary assessment of the benefits (removing pathology, relieving raised intracranial pressure, obtaining tissue diagnosis) versus risks (neurological deficit, infection, haemorrhage) on an individual patient basis.

Brain tumours — both primary (arising from brain tissue) and secondary (metastases from lung, breast, colorectal, melanoma, renal cell carcinoma, and other primaries) — are among the most common indications for brain surgery. Craniotomy and surgical resection is the first-line treatment for most operable brain tumours, providing tissue diagnosis, reducing tumour bulk to relieve symptoms, and improving the response to subsequent radiotherapy and chemotherapy. High-grade gliomas (glioblastoma, GBM — the most common primary malignant brain tumour in adults) benefit from maximal safe resection; extent of resection is independently associated with improved survival in multiple large series.

Intracranial vascular conditions requiring surgery include cerebral aneurysm (surgical clipping to prevent rupture or re-rupture after subarachnoid haemorrhage), arteriovenous malformations (AVM) requiring surgical or radiosurgical intervention for haemorrhage risk reduction, cavernous malformations causing epilepsy or haemorrhage, and intracerebral haematoma (blood clot within brain tissue) from hypertensive haemorrhage or trauma requiring surgical evacuation when causing significant mass effect. Hydrocephalus (excess cerebrospinal fluid causing raised intracranial pressure) is managed with CSF diversion procedures — ventriculoperitoneal shunting or neuroendoscopic third ventriculostomy (ETV). Epilepsy surgery — temporal lobectomy, hemispherotomy, corpus callosotomy, and responsive neurostimulation (RNS) — is indicated for drug-resistant epilepsy where a resectable epileptic focus is identified. Traumatic brain injuries may require decompressive craniectomy (removal of a large skull section to allow brain swelling) or evacuation of extradural and subdural haematomas.

Eligibility for brain surgery requires comprehensive pre-operative evaluation by the neurosurgical and neurological multidisciplinary team. For brain tumour surgery, the decision depends on tumour location (eloquent versus non-eloquent cortex), size, imaging characteristics suggesting histology, patient age, performance status (Karnofsky Performance Status or ECOG), and symptoms. Advanced neuroimaging — including functional MRI (fMRI) to map language and motor areas, diffusion tensor imaging (DTI) to map white matter tracts (the corticospinal tract and arcuate fasciculus), and MR spectroscopy — is performed to plan safe surgical corridors avoiding eloquent structures.

For vascular surgery (aneurysm clipping), anatomy of the aneurysm (neck dimensions, orientation, rupture status), patient age, neurological grade (Hunt and Hess scale), and availability of endovascular coiling as an alternative are central considerations. For epilepsy surgery, patients must have medically refractory focal epilepsy (failure of at least two appropriately chosen anti-epileptic drugs), with a clearly identified epileptic focus concordant across video-EEG, MRI, and neuropsychological assessment. Awake craniotomy — surgery performed with the patient awake but sedated, allowing direct cortical mapping to preserve speech and motor function — is indicated when the tumour or lesion is in or adjacent to eloquent cortex; patients must be cooperative, psychologically stable, and able to participate in intraoperative testing.

Standard craniotomy involves scalp incision, reflection of the scalp flap, drilling burr holes, and cutting a bone flap with a craniotome (neurosurgical saw). Once the dura (the innermost meningeal membrane) is opened, the neurosurgeon approaches the target using neuronavigation, microscopy, and ultrasonic aspiration (CUSA — Cavitron Ultrasonic Surgical Aspirator) or laser (CO2, Nd:YAG) for tumour removal. At the end of the procedure, the dura and bone flap are closed and secured, and the scalp is sutured.

Minimally invasive neurosurgery approaches include the supraorbital keyhole craniotomy (Perneczky approach — a 2.5 cm incision behind the hairline above the eyebrow, for anterior fossa and sellar tumours), the retrosigmoid/suboccipital keyhole approach for posterior fossa and cerebellopontine angle tumours, and the expanded endoscopic endonasal approach (EEEA) for pituitary adenomas, craniopharyngiomas, and midline skull base tumours without any visible external incision. Endoscopic endonasal surgery uses an endoscope introduced through the nostril to access tumours at the skull base — it provides excellent visualisation, avoids brain retraction, and achieves complete gross total resection in 80–90% of pituitary macroadenomas. Intraoperative MRI, increasingly available at quaternary neurosurgical centres, allows real-time visualisation of residual tumour during resection, improving gross total resection rates by 15–20%. Fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) causes tumour cells to fluoresce pink-red under blue light, enabling surgeons to distinguish viable malignant tissue from infiltrated normal brain more reliably.

Brain surgery, when performed by an experienced neurosurgeon in an appropriately equipped centre, achieves its primary objectives — removal of pathological tissue, relief of raised intracranial pressure, tissue diagnosis, and neurological improvement — in the majority of patients. For glioblastoma (GBM), a meta-analysis published in Neuro-Oncology demonstrated that gross total resection (>98% tumour volume removed) independently improves median overall survival by approximately 4–5 months compared with biopsy alone, and by 2–3 months compared with subtotal resection, beyond the benefit provided by adjuvant chemoradiotherapy (Stupp protocol — temozolomide with radiotherapy).

For benign tumours — meningiomas, pituitary adenomas, acoustic neuromas (vestibular schwannomas) — complete surgical removal is frequently curative. The Gamma Knife Radiosurgery Perfexion system and the Accuray CyberKnife can achieve comparable control rates for selected small tumours, but surgical resection remains the treatment of choice for large tumours causing mass effect or neurological compression. Epilepsy surgery (anterior temporal lobectomy for temporal lobe epilepsy from mesial temporal sclerosis) achieves seizure freedom in approximately 60–70% of patients at two years, with a further 20% achieving significant reduction in seizure frequency — a life-changing result in patients who have had daily or weekly seizures for years.

Brain surgery carries significant potential risks, which must be weighed carefully against the expected benefit. The principal risks include neurological deficit — new or worsened weakness, speech or language dysfunction (dysphasia/aphasia), visual field defect, cognitive impairment, memory disturbance, or personality change. The risk of any new neurological deficit depends critically on tumour location relative to eloquent areas, and on the surgical technique used. Eloquent area tumours (motor cortex, speech areas) carry 5–15% risk of permanent neurological deficit with modern intraoperative mapping techniques; non-eloquent area tumours carry far lower neurological risk.

Intracranial haemorrhage — intraoperative or post-operative — is a potentially life-threatening complication occurring in approximately 1–2% of craniotomies; most cases are managed with re-operation. Post-operative cerebral oedema causing raised intracranial pressure is managed with corticosteroids (dexamethasone), mannitol, and, in severe cases, craniectomy. Infection (meningitis, brain abscess, wound infection) occurs in approximately 1–3% of craniotomies. CSF leak manifesting as rhinorrhoea (nasal drip) occurs particularly after skull base surgery and may require lumbar drain or surgical repair. Deep vein thrombosis and pulmonary embolism are significant perioperative risks given the prolonged operative duration.

The immediate post-operative period is managed in the neurosurgical intensive care unit or high-dependency unit. Neuro-observations (level of consciousness, pupil responses, limb movements) are performed hourly. A post-operative CT scan within 24 hours detects early complications (haemorrhage, oedema, pneumocephalus). For tumour surgery, an MRI within 48–72 hours (the 'MRI window') before enhancement artefact makes assessment difficult is the standard to confirm extent of resection.

Rehabilitation — physiotherapy, occupational therapy, speech and language therapy, neuropsychology — commences within 2–3 days post-operatively in patients with deficits. Hospital stay ranges from 5 to 14 days depending on recovery trajectory. After discharge, patients are reviewed at 2 weeks for wound check, and follow-up intervals (4–6 weekly for tumour patients receiving adjuvant treatment, 3-monthly for surveillance) are determined by the underlying condition. Return to driving is restricted pending DVLA/equivalent authority medical clearance. Cognitive recovery — particularly from frontal lobe surgery or from brain oedema — may take weeks to months; neuropsychological support and brain rehabilitation programmes support this process.

Brain surgery costs reflect the highly specialised surgical team, complex intraoperative equipment (neuronavigation, intraoperative neurophysiology, surgical microscope, endoscopic systems, intraoperative MRI), and prolonged intensive care requirements. In the United States, craniotomy for brain tumour with NICU/ICU stay costs USD 80,000–200,000+ depending on tumour complexity and length of stay. In the United Kingdom, NHS coverage applies for standard indications; private brain surgery costs GBP 20,000–60,000.

For international patients, India is the leading destination for cost-effective brain surgery at internationally accredited centres. Apollo Hospitals, Fortis Hospital, Narayana Health, and Kokilaben Dhirubhai Ambani Hospital have neurosurgery units equipped with intraoperative neuronavigation, awake craniotomy capability, 7T MRI, and internationally trained neurosurgeons. Brain surgery costs at leading Indian centres range from USD 7,000–18,000 all-inclusive — savings of 80–90% versus US rates. Thailand (Bumrungrad, Bangkok Hospital) and Turkey (Memorial Hospitals, Anadolu Medical Centre) are mid-cost alternatives with high-quality neurosurgical programmes. Patients should seek centres with NABH or JCI accreditation and confirm neurosurgeon fellowship training.

For many brain conditions, non-surgical alternatives are the first-line approach. Medical management with anti-epileptic drugs, corticosteroids, osmotic agents, and anti-tumour medications (bevacizumab for GBM-associated oedema) can manage many symptoms non-surgically. Stereotactic radiosurgery (Gamma Knife, CyberKnife, TrueBeam EDGE) delivers highly focused radiation to intracranial tumours and vascular malformations in 1–5 fractions, without opening the skull, and is the primary modality for brain metastases <3 cm, vestibular schwannomas, meningiomas, and AVMs. It is not suitable for large tumours causing mass effect or requiring tissue diagnosis.

Endovascular neurosurgery — performing procedures through catheters introduced via the femoral artery — is the preferred treatment for most unruptured cerebral aneurysms (coiling is favoured over clipping for many anatomically suitable aneurysms, based on the ISAT trial) and for AVM embolisation (often as pre-operative adjunct). For functional neurosurgical conditions, deep brain stimulation (DBS) is the standard surgical treatment for Parkinson's disease, essential tremor, and dystonia — involving electrode implantation in the subthalamic nucleus or globus pallidus under stereotactic guidance. Vagus nerve stimulation and responsive neurostimulation (RNS) are minimally invasive surgical alternatives for drug-resistant epilepsy where open resective surgery is not possible.